Clinical trials: Neurocognitive Disorder
- Condition Neurocognitive Disorder
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Alzheimer Disease, Healthy Aging
Telerehabilitation Alzheimer's Disease Usability (TADU)
Usability evaluation of BrightGo cognitive telerehabilitation system. An experimental system was developed to enhance standard of care (medication effect) for Early Alzheimer's Disease populations.
- Trial name
- TADU (NCT04731311)
- Testing
- Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Bright Cloud International Corp
Dementia, Frontotemporal
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants
This is a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of VES001 in a two part followed by a…
- Trial name
- SORT-IN-1 (NCT06226064)
- Testing
- VES001
- Where
- Netherlands
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Vesper Biotechnologies ApS
Alzheimer Disease
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531
To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy Japanese young male and elderly subjects.To provide the pharmacokinetics (PK) and pharmacodynamics (PD)…
- Trial name
- NCT00479349
- Testing
- SAM-531
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
This study will investigate the performance of physician readers trained to read florbetapir-PET scans using electronic media training.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01550549
- Testing
- florbetapir F 18
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
To test that LY450139, a gamma-secretase inhibitor, will reduce the rate of newly synthesize Amyloid Beta by determining the amount of newly synthesized 13C6 leucine-labeled Amyloid Beta in lumbar cerebrospinal fluid from…
- Trial name
- NCT00765115
- Testing
- LY450139
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Alzheimer Disease (AD)
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Trial name
- DU-PRISM (NCT07142278)
- Testing
- DUVAX 200 µg, DUVAX 400 µg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Stroke Sequelae, Cognitive Impairment
Remote Bimanual Virtual Rehabilitation Post CVD
The aim of the study is to develop the BrightBrainer G (grasp), a game-based upper-extremity motor and cognitive rehabilitation system using custom virtual reality simulations.
- Conditions
- Stroke Sequelae, Cognitive Impairment, Depression
- Trial name
- NCT04713384
- Testing
- Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Grigore Burdea
Quality of Life (QOL), Anxiety
Testing the Efficacy of the "Syd" App on Improving Quality of Life and Mental Health Among University Students in the Kingdom of Saudi Arabia
The goal of this clinical trial is to learn if using the "See Yourself Differently" (syd) app can help improve quality of life and mental health for university students in Saudi Arabia.
- Conditions
- Quality of Life (QOL), Anxiety, Stress, Affect (Mental Function)
- Trial name
- NCT06979778
- Testing
- See Yourself Differently (syd) mobile app
- Where
- Saudi Arabia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- iamYiam Limited
Mild Cognitive Impairment
Exploratory Trial in Healthy Adults With Mild Cognitive Impairment,16-week Intervention With Mitocholine™
To evaluate the effect of 16-weeks consumption of Mitocholine on Executive Function and Homocysteine levels in a population experiencing Mild Cognitive Impairment.
- Trial name
- NCT05690724
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mitocholine Ltd
Cognitive Impairment
Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects
This is a single center, double-blind, placebo and positive-controlled, randomized, partial 6-way cross-over study to investigate the pharmacodynamics and pharmacokinetics of CEP-26401 (5, 25, and 125 μg) following single-dose…
- Trial name
- NCT01903824
- Testing
- CEP-26401, donepezil hydrochloride, modafinil
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Healthy Volunteer
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
This study is designed to obtain basic information on three PET imaging tracers developed to detect tau pathology in the brain. In this study, healthy control participants and participants with AD will be studied.
- Trial name
- NCT02187627
- Testing
- [11C]RO6924963, [11C]RO6931643, [18F]RO6958948
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects
To assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of lecozotan SR in healthy young and elderly subjects.
- Trial name
- NCT00366483
- Testing
- Lecozotan SR
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Crownlands Observing Progression With Neurons Study
The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
- Trial name
- CROWN-I (NCT07611396)
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Crownlands
Alzheimer's Disease
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
This study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and…
- Trial name
- NCT01716897
- Testing
- E2609
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Dementia, Prisoners
Computer-Based Learning to Enhance Dementia Care in Prison
The mission of corrections is to provide care, custody, and control for incarcerated individuals. United States prisons are required by law to provide adequate care for growing numbers of older people who are incarcerated-a group…
- Trial name
- NCT05497882
- Testing
- E-Learning Prototype for Dementia Care
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Alzheimer Disease, Early Onset, Alzheimer Disease
A Safety Study of PTI-125 in Healthy Volunteers
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
- Trial name
- NCT03784300
- Testing
- 50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics